DiaMedica Therapeutics Inc. (DMAC) Research
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Market snapshot
- Symbol
- DMAC
- Price
- $5.85
- Day change
- +2.09%
- Market cap
- $315.2M
- P/E ratio
- -8.97x
- 52-week range
- 3.475-10.4195
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $8.33
Recent news
- Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
Peer companies
Recent insider activity
- Parsons James T. — A-Award (10095 shares) on 2026-01-02
- Giuffre Randall Michael — A-Award (6175 shares) on 2026-01-02
- Semba Charles Pauling — A-Award (3355 shares) on 2026-01-02
- STAHLBERG JAN — P-Purchase (73099 shares) on 2025-11-25
- STAHLBERG JAN — P-Purchase (40253 shares) on 2025-11-24
Open DiaMedica Therapeutics Inc. (DMAC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.